The archive · Health & Care · Strategic decision · 2021–2026
Lindus Health bets software-first trials can displace the CRO oligopoly
London startup rebuilds clinical trials end-to-end with automation, enrolling 35,000+ patients before a $55M Balderton-led Series B.
Lindus Health
What the business is
Lindus Health (now Lindus Therapeutics) is a tech-first contract research organization that runs end-to-end clinical trials — protocol design, patient recruitment, data capture, telehealth visits and trial staff — on its Citrus platform, and has expanded into in-licensed drug development.
Starting capital：~$6M in early funding from Creandum, Peter Thiel, Firstminute and Seedcamp; $18M Series A (August 2023); $55M Series B led by Balderton Capital (January 2025); roughly $80M total including grants.
How it started
Founded in London in 2021 by Meri Beckwith (ex-OMERS Ventures), Michael Young (former special adviser to the UK Prime Minister on life sciences) and Nik Haldimann, after Beckwith watched healthtech companies struggle with trial outcomes and Young concluded trials were the bottleneck between research and patients. They raised ~$6M from Creandum, Peter Thiel and others before an $18M Series A in August 2023.
What happened
By August 2023 Lindus said it had delivered 80+ trials across depression, diabetes and insomnia, touting itself as the 'anti-CRO'. In January 2025 it raised a $55M Series B led by Balderton, with Creandum, Firstminute, Seedcamp and Visionaries Club, reporting 35,000+ patients enrolled and started moving its headquarters from the UK to the US. In March 2025 it launched ReMEdi, a fully virtual Phase 2 trial for ME/CFS with Tiefenbacher Group, using its Citrus eClinical platform, Oura rings for remote monitoring and telehealth visits.
How it ended up
Still running and expanded: by 2026 the company had rebranded as Lindus Therapeutics, adding in-licensed drug asset development on top of its trial execution business; its site claims $80M raised, 45+ completed trials and 120 staff across the US and Europe.
Background
Lindus Health is a London-born 'anti-CRO': instead of selling point tools to contract research organizations, it runs entire clinical trials — protocol design, recruitment, data capture, telehealth visits and the clinical staff — on its own software platform, Citrus. The pitch is that a tech-first operator can fix the chronic dysfunction of an industry where trials run late, over budget and with error-prone manual processes.
The founders came at the problem from both sides: Meri Beckwith, a former OMERS Ventures investor, had seen portfolio companies frustrated with trials; Michael Young, a former special adviser to the UK Prime Minister on life sciences, concluded trials were the bottleneck between drug R&D and patients. They started with common, comparatively simple conditions — depression, diabetes, insomnia, later acne and weight management — and used ML to draft protocols and monitor data in real time.
Traction built steadily: 80+ delivered trials by 2023, an $18M Series A from Creandum and Peter Thiel, then a $55M Series B led by Balderton in January 2025 when the company said it had enrolled and treated more than 35,000 patients. By 2026 the company had rebranded as Lindus Therapeutics and moved beyond pure trial services into in-licensed drug development, claiming $80M raised, 45+ completed trials and 120 staff.
What has to be true
- The 'own the entire trial' wedge matched where the pain actually was — end-to-end dysfunction — instead of competing on one feature.
- Starting with common, neglected conditions kept trials simple enough for a startup to run end-to-end and made recruitment easier.
- ML protocol generation and real-time data monitoring attacked the two most manual, error-prone stages of trial work.
- Creandum and Thiel's early checks plus a growing delivered-trial record made the larger 2025 round defensible.
- Expanding from CRO services into drug asset development turns execution capability into longer-term upside.
What can be applied
In regulated, relationship-driven industries, software wins as a services business first: Lindus ran whole trials for neglected conditions, then converted that capability into owning drug assets.
Aftermath
As of 2026-09-02 Lindus is scaling as Lindus Therapeutics: it runs 45+ phase I-IV trials across the US, UK and Europe, employs ~120 people, and has expanded into in-licensed drug development with flexible licensing and co-development deal structures. It reports $80M total funding and says 82% of its trials completed enrollment on or ahead of timeline.
Sources
- Lindus Health, a UK clinical trials startup backed by Peter Thiel, raises $18M
- Lindus Health raises $55M to 'fix the broken clinical trial industry'
- Lindus Health and Tiefenbacher Group Launch Virtual Clinical Trial for ME/CFS Treatment
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card